Design and Synthesis of Truncated EGF-A Peptides that Restore LDL-R Recycling in the Presence of PCSK9 In Vitro-Reference-Cited by-同舟云学术

Design and Synthesis of Truncated EGF-A Peptides that Restore LDL-R Recycling in the Presence of PCSK9 In Vitro

Published:2014-02 Issue:2 Volume:21 Page:284-294
ISSN:1074-5521
Container-title:Chemistry & Biology
language:en
Short-container-title:Chemistry & Biology

Author:

Schroeder Christina I.,Swedberg Joakim E.,Withka Jane M.,Rosengren K. Johan,Akcan Muharrem,Clayton Daniel J.,Daly Norelle L.,Cheneval Olivier,Borzilleri Kris A.,Griffor Matt,Stock Ingrid,Colless Barbara,Walsh Phillip,Sunderland Philip,Reyes Allan,Dullea Robert,Ammirati Mark,Liu Shenping,McClure Kim F.,Tu Meihua,Bhattacharya Samit K.,Liras Spiros,Price David A.,Craik David J.

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,Molecular Medicine,General Medicine,Biochemistry

Reference47 articles.

1. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia;Abifadel;Nat. Genet.,2003

2. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol;Benjannet;J. Biol. Chem.,2004

3. Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants;Bottomley;J. Biol. Chem.,2009

4. A receptor-mediated pathway for cholesterol homeostasis;Brown;Science,1986

5. Crystallography & NMR system: a new software suite for macromolecular structure determination;Brünger;Acta Crystallogr. D Biol. Crystallogr.,1998

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition;European Journal of Clinical Investigation;2024-06-26

2. Potential acridinedione derivatives for the development of a heterobifunctional PROTAC for targeted degradation of PCSK9 protein;Applied Materials Today;2024-06

3. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside;Signal Transduction and Targeted Therapy;2024-01-08

4. PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and Their Future Perspectives;Current Molecular Pharmacology;2023-12

5. The Link between miRNAs and PCKS9 in Atherosclerosis;Current Medicinal Chemistry;2023-11-16